Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRBP |
---|---|---|
09:32 ET | 394 | 41.86 |
09:34 ET | 5100 | 41.55 |
09:38 ET | 166 | 42 |
09:39 ET | 348 | 41.53 |
09:41 ET | 1800 | 42 |
09:45 ET | 200 | 41.52 |
09:56 ET | 100 | 41.975 |
09:57 ET | 435 | 41.5376 |
10:01 ET | 100 | 41.275 |
10:06 ET | 900 | 41.74 |
10:12 ET | 100 | 41.58 |
10:15 ET | 901 | 42.36 |
10:17 ET | 100 | 41.98 |
10:24 ET | 400 | 41.88 |
10:26 ET | 100 | 41.88 |
10:28 ET | 783 | 41.7 |
10:32 ET | 278 | 41.84 |
10:33 ET | 2800 | 41.94 |
10:35 ET | 608 | 42.25 |
10:42 ET | 100 | 42.21 |
10:46 ET | 200 | 42.145 |
10:48 ET | 100 | 42.17 |
10:50 ET | 100 | 42.19 |
10:51 ET | 2950 | 41.92 |
11:00 ET | 2100 | 42 |
11:02 ET | 400 | 42.35 |
11:04 ET | 2600 | 42.1 |
11:06 ET | 120 | 41.985 |
11:08 ET | 1800 | 41.92 |
11:09 ET | 900 | 42.2 |
11:15 ET | 440 | 42.125 |
11:20 ET | 100 | 42.095 |
11:26 ET | 5890 | 42.29 |
11:27 ET | 417 | 42.41 |
11:31 ET | 100 | 42.5 |
11:42 ET | 3635 | 42.5 |
11:44 ET | 1433 | 42.95 |
11:45 ET | 416 | 43.16 |
11:47 ET | 100 | 43.11 |
11:56 ET | 100 | 43.1 |
12:02 ET | 100 | 43.17 |
12:05 ET | 100 | 43.13 |
12:07 ET | 200 | 43.13 |
12:09 ET | 938 | 43.34 |
12:16 ET | 100 | 43.52 |
12:25 ET | 100 | 43.55 |
12:27 ET | 550 | 43.645 |
12:30 ET | 800 | 43.59 |
12:32 ET | 312 | 43.79 |
12:36 ET | 200 | 43.77 |
12:38 ET | 1969 | 43.5 |
12:41 ET | 250 | 43.5154 |
12:43 ET | 300 | 43.48 |
12:52 ET | 650 | 43.365 |
12:56 ET | 600 | 43.195 |
12:57 ET | 200 | 43.2 |
01:03 ET | 200 | 42.89 |
01:06 ET | 700 | 42.78 |
01:10 ET | 877 | 42.73 |
01:12 ET | 1500 | 43 |
01:21 ET | 661 | 42.995 |
01:24 ET | 200 | 43.1 |
01:26 ET | 100 | 43 |
01:30 ET | 100 | 43.01 |
01:33 ET | 100 | 42.88 |
01:35 ET | 315 | 43.0145 |
01:37 ET | 800 | 42.825 |
01:39 ET | 900 | 43 |
01:50 ET | 141 | 43.35 |
02:00 ET | 200 | 43.36 |
02:02 ET | 100 | 43.37 |
02:06 ET | 100 | 43.43 |
02:11 ET | 1233 | 43.58 |
02:13 ET | 800 | 43.73 |
02:15 ET | 100 | 43.92 |
02:22 ET | 225 | 44.18 |
02:26 ET | 300 | 44.03 |
02:27 ET | 100 | 44.14 |
02:31 ET | 126 | 44.18 |
02:36 ET | 100 | 44.085 |
02:44 ET | 200 | 44.04 |
02:45 ET | 100 | 44.21 |
02:49 ET | 2577 | 44.31 |
02:51 ET | 1100 | 44.07 |
02:54 ET | 300 | 44 |
02:58 ET | 300 | 44.005 |
03:00 ET | 100 | 44 |
03:05 ET | 330 | 43.82 |
03:12 ET | 145 | 43.92 |
03:14 ET | 100 | 43.92 |
03:16 ET | 200 | 43.91 |
03:18 ET | 1048 | 43.74 |
03:23 ET | 200 | 43.615 |
03:25 ET | 200 | 43.405 |
03:27 ET | 100 | 43.195 |
03:30 ET | 300 | 43.19 |
03:32 ET | 2672 | 43.335 |
03:34 ET | 100 | 43.335 |
03:36 ET | 100 | 43.09 |
03:38 ET | 400 | 43.02 |
03:39 ET | 400 | 43.02 |
03:41 ET | 2842 | 43.42 |
03:43 ET | 248 | 43.23 |
03:45 ET | 1100 | 42.94 |
03:48 ET | 3600 | 43.065 |
03:50 ET | 1300 | 42.83 |
03:52 ET | 4600 | 42.655 |
03:54 ET | 9807 | 42.74 |
03:56 ET | 2820 | 42.46 |
03:57 ET | 2941 | 42.68 |
03:59 ET | 2253 | 42.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | 457.4M | -6.1x | --- |
Annexon Inc | 446.4M | -3.3x | --- |
Korro Bio Inc | 475.7M | -1.2x | --- |
Nkarta Inc | 478.5M | -2.9x | --- |
Neurogene Inc | 488.1M | -8.2x | --- |
Cabaletta Bio Inc | 491.9M | -5.9x | --- |
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $457.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.52 |
EPS | $-6.97 |
Book Value | $-1.56 |
P/E Ratio | -6.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.